XenoPort, Inc. is founded in 1999. The company operates in the Manufacturing, Pharmaceuticals sector, providing Laboratories: Biotechnology, Laboratories: Research & Testing, and more to its customers.
XenoPort, Inc. specializes in Neurological disorder treatments, Drug development, Commercialization of pharmaceuticals, Parkinson's disease treatments, Multiple sclerosis treatments, Psoriasis treatments, and offers services including Horizant® (gabapentin enacarbil) Extended-Release Tablets, Regnite® (gabapentin enacarbil) Extended-Release Tablets.
Total Rounds
US$ 20M
Last Round
US$ 20M
Rounds
1